山东大学学报 (医学版) ›› 2023, Vol. 61 ›› Issue (1): 94-99.doi: 10.6040/j.issn.1671-7554.0.2022.1111
巨艳丽1,王丽华1,成芳1,黄凤艳1,陈学禹1,贾红英1,2
JU Yanli1, WANG Lihua1, CHENG Fang1, HUANG Fengyan1, CHEN Xueyu1, JIA Hongying1,2
摘要: 目的 基于分化型甲状腺癌(DTC)患者的临床资料及放射学参数,通过机器学习算法构建放射性碘治疗(RAI)疗效的预测模型。 方法 选取2015年12月至2020年12月于山东大学第二医院核医学科接受RAI治疗的1 642例DTC患者为研究对象,在RAI治疗结束的6个月后评估其治疗疗效,筛选与疗效相关的核心特征进行机器学习建模。将研究对象按就诊时间(2019年7月)划分为训练集(n=973)和验证集(n=669),于训练集中利用Logistic、随机森林、支持向量机、Adaboost 4种方法进行模型构建,利用受试者工作特征曲线下面积(AUC)、灵敏度和特异度评估模型的性能,绘制校准曲线及决策曲线评估模型的准确度和临床受益性,并在验证集中评估模型外部稳定性。 结果 4种模型的预测性能较高,稳定性较好,预测精度和净收益高于目前临床常规应用的肿瘤-淋巴结-转移(TNM)分期和复发风险分层。Logistic模型表现最佳,其AUC在训练集中为0.827、验证集中为0.869。 结论 基于机器学习构建的术后RAI治疗疗效预测模型有较高的预测性能,由此构建的列线图可实现个体化精准预测。
中图分类号:
| [1] Cabanillas ME, McFadden DG, Durante C. Thyroid cancer [J]. Lancet, 2016, 388(10061): 2783-2795. [2] Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy [J]. Thyroid, 2006, 16(12): 1229-1242. [3] Ito Y, Higashiyama T, Takamura Y, et al. Prognosis of patients with papillary thyroid carcinoma showing postoperative recurrence to the central neck [J]. World J Surg, 2011, 35(4): 767-772. [4] Yang X, Liang J, Li T, et al. Preablative stimulated thyroglobulin correlates to new therapy response system in differentiated thyroid cancer [J]. J Clin Endocrinol Metab, 2016, 101(3): 1307-1313. [5] Van CB, Wynants L. Machine learning in medicine [J]. N Engl J Med, 2019, 380(26): 2588. doi: 10.1161/CIRCULATIONAHA.115.001593. [6] May M. Eight ways machine learning is assisting medicine [J]. Nat Med, 2021, 27(1): 2-3. [7] Stephen JS, Mireia CO, Suet FC, et al. Multi-omic machine learning predictor of breast cancer therapy response [J]. Nature, 2022, 601(7894): 623-629. [8] Chaudhary K, Poirion OB, Lu L, et al. Deep learning-based multi-omics integration robustly predicts survival in liver cancer [J]. Clin Cancer Res, 2018, 24(6): 1248-1259. [9] Kather JN, Pearson AT, Halama N, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer [J]. Nat Med, 2019, 25(7): 1054-1056. [10] Gould MK, Huang BZ, Tammemagi MC, et al. Machine learning for early lung cancer identification using routine clinical and laboratory data [J]. Am J Respir Crit Care Med, 2021, 204(4): 445-453. [11] Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer [J]. Thyroid, 2016, 26(1): 1-133. [12] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218-241. Chinese Society of Nuclear Medicine. Guidelines for radioiodine therapy of differentiated thyroid cancer(2021 edition)[J]. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2021, 41(4): 218-241. [13] Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer(eighth edition): what changed and why [J]. Thyroid, 2017, 27(6): 751-756. [14] Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J]. Thyroid, 2009, 19(11): 1167-1214. [15] Grani G, Zatelli MC, Alfò M, et al. Real-world performance of the American Thyroid Association risk estimates in predicting 1-year differentiated thyroid cancer outcomes: a prospective multicenter study of 2000 patients [J]. Thyroid, 2021, 31(2): 264-271. [16] Tuttle RM, Alzahrani AS. Risk stratification in differentiated thyroid cancer: from detection to final follow-up [J]. J Clin Endocrinol Metab, 2019, 104(9): 4087-4100. [17] 林岩松, 李娇. 2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南》解读:分化型甲状腺癌~131I治疗新进展[J]. 中国癌症杂志, 2016, 26(1): 1-12. LIN Yansong, LI Jiao. The interpretation of 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid carcinoma: new progress in radioactive iodine therapy of differentiated thyroid carcinoma [J]. China Oncology, 2016, 26(1): 1-12. [18] Shen FC, Hsieh CJ, Huang IC, et al. Dynamic risk estimates of outcome in Chinese patients with well-differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation [J]. Thyroid, 2017, 27(4): 531-536. [19] 周倩, 王瑞华, 刘保平, 等. 高危分化型甲状腺癌手术及131I治疗后疗效分类及影响因素分析[J]. 中华核医学与分子影像杂志, 2021, 41(11): 664-669. ZHOU Qian, WANG Ruihua, LIU Baoping, et al. Classification of therapeutic effect and influencing factors in patients with high-risk differentiated thyroid carcinoma after surgery and 131I treat [J]. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2021, 41(11): 664-669. [20] Prpi c M, Franceschi M, Romi c M, et al. Thyroglobulin as a tumor marker in differentiated thyroid cancer-clinical considerations [J]. Acta Clin Croat, 2018,57(3): 518-527. [21] Wong KCW, Ng TY, Yu KS, et al. The use of post-ablation stimulated thyroglobulin in predicting clinical outcomes in differentiated thyroid carcinoma-what cut-off values should we use [J]. Clin Oncol(R Coll Radiol), 2019, 31(2): e11-e20. [22] Jayasekara J, Jonker P, Lin JF, et al. Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer [J]. Surgery, 2020, 167(1): 40-45. [23] Nóbrega G, Cavalcanti M, Leite V, et al. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine [J]. Endocrine, 2022, 76(3): 642-647. [24] Pan M, Li Z, Jia M, et al. Combination of stimulated thyroglobulin and antithyroglobulin antibody predicts the efficacy and prognosis of(131)I therapy in patients with differentiated thyroid cancer following total thyroidectomy: a retrospective study [J]. Front Endocrinol(Lausanne), 2022, 13: 857057. doi: 10.3389/fendo.2022.857057. [25] Prpic M, Kust D, Kruljac I, et al. Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: a cohort study of 740 patients [J]. Head Neck, 2017, 39(1): 109-115. |
| [1] | 廖原,门丹,李一帆,李怀臣,龙飞,刘铱. PM2.5短期暴露对结核病发病风险的个体精准评估[J]. 山东大学学报 (医学版), 2026, 64(3): 116-123. |
| [2] | 刘禹,霍娅娅,龚丞,梁婷,李斌. 基于机器学习的骨科生物材料设计与优化[J]. 山东大学学报 (医学版), 2026, 64(2): 22-33. |
| [3] | 王建民,李晓峰,由志涛,董圣杰,赵宇驰,李占菊,邹德鑫,张剑锋,孙涛,杜伟. 基于可解释机器学习的后路腰椎椎体间融合术后慢性疼痛风险预测模型构建[J]. 山东大学学报 (医学版), 2026, 64(2): 78-88. |
| [4] | 孙爽爽,仉率杰,张伯韬,袁莹,于媛媛,薛付忠. 基于真实世界研究的18~50岁人群急性缺血性卒中影响因素[J]. 山东大学学报 (医学版), 2025, 63(9): 40-46. |
| [5] | 申路佳,逯天威,巩伟明,赵岩松,王淑康,袁中尚. 代谢风险评分在2型糖尿病人群心血管结局预测中的应用[J]. 山东大学学报 (医学版), 2025, 63(8): 69-78. |
| [6] | 王丽云,高天勤,刘雨佳,陈青,陈柳,沙凯辉. 基于机器学习产后压力性尿失禁风险预测模型的构建及验证[J]. 山东大学学报 (医学版), 2025, 63(6): 55-66. |
| [7] | 陈瑛翼,游倩,王意,张帆,李凤,季舒铭,徐浩源,饶志勇. 办公室职员肌肉质量减少预测模型的开发与验证[J]. 山东大学学报 (医学版), 2025, 63(4): 26-35. |
| [8] | 王宝炫,焦杰,张厚君,刘奇,于冠英. 衰弱与肌少症评估在胃肠道肿瘤术后结局预测中的应用与展望[J]. 山东大学学报 (医学版), 2025, 63(4): 51-58. |
| [9] | 赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 131I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28. |
| [10] | 李永,崔书君,杨飞,张凡,殷晓霞. 基于增强MRI的亚区域影像组学模型可预测乳腺癌患者新辅助化疗后的病理完全反应[J]. 山东大学学报 (医学版), 2025, 63(1): 81-89. |
| [11] | 孙丽娜,白红艳,牛宗格,张福帅,曲仪庆. 基于SII构建及评价预测ARDS住院死亡率的在线临床风险模型[J]. 山东大学学报 (医学版), 2024, 62(7): 10-20. |
| [12] | 王静,刘晓菲,曾荣,许长娟,张锦涛,董亮. 基于机器学习算法鉴定哮喘的坏死性凋亡相关生物标志物[J]. 山东大学学报 (医学版), 2024, 62(7): 21-32. |
| [13] | 郭振江,王宁,赵光远,杜立强,崔朝勃,刘防震. 基于机器学习建立术前预测近端胃癌食管切缘阳性模型[J]. 山东大学学报 (医学版), 2024, 62(7): 78-83. |
| [14] | 梁永媛,蔡培飞,郑桂喜. 基于多检验变量和机器学习算法的结肠癌诊断模型建立及价值评估[J]. 山东大学学报 (医学版), 2024, 62(2): 51-59. |
| [15] | 刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68. |
|
||